Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
652.34B
Market cap652.34B
Price-Earnings ratio
31.37
Price-Earnings ratio31.37
Dividend yield
1.95%
Dividend yield1.95%
Average volume
6.58M
Average volume6.58M
High today
$272.25
High today$272.25
Low today
$269.26
Low today$269.26
Open price
$271.75
Open price$271.75
Volume
831.59K
Volume831.59K
52 Week high
$281.07
52 Week high$281.07
52 Week low
$175.91
52 Week low$175.91

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $270.69, with a market capitalization of 652.34B. The stock trades at a price-to-earnings (P/E) ratio of 31.37 and offers a dividend yield of 1.95%.

During the trading session on 2026-09-25, Johnson & Johnson(JNJ) shares reached a daily high of $272.25 and a low of $269.26. At a current price of $270.69, the stock is +0.5% higher than the low and still -0.6% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 831.59K, versus its average volume of 6.58M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $175.91.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $175.91.

JNJ News

Benzinga 14m
Johnson & Johnson Clinical Trials Show Progress Across Key Therapies

Johnson & Johnson (NYSE:JNJ) announced positive findings from key clinical evaluations testing its therapies, Tremfya and Carvykti, across psoriatic arthritis a...

Johnson & Johnson Clinical Trials Show Progress Across Key Therapies
24/7 Wall St. 16m
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade

Investing ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade AbbVie and Johnson and Johnson both trade near 52-week highs...

ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
TipRanks 4h
Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study

Johnson & Johnson announced that Tremfya met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflamm...

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
22.2%
Sell
7.4%

More JNJ News

Simply Wall St 6h
Johnson & Johnson Phase 3 Myeloma Data Recasts Long Term Survival Expectations

Johnson & Johnson (NYSE: JNJ) reported new Phase 3 MajesTEC-3 results for TECVAYLI plus DARZALEX FASPRO in relapsed/refractory multiple myeloma. The MajesTEC-3...

Johnson & Johnson Phase 3 Myeloma Data Recasts Long Term Survival Expectations
New York Times 14h
Lakers’ new core? JJ Redick calls Walker Kessler ‘perfect fit’ for Luka Dončić, Austin Reaves - The New York Times

...

Lakers’ new core? JJ Redick calls Walker Kessler ‘perfect fit’ for Luka Dončić, Austin Reaves - The New York Times
24/7 Wall St. 22h
CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More

Investing CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More When a retiree compares a federally insured CD to a dividend stock that ha...

CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More
Nasdaq 1d
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?

Key Points Bristol Myers Squibb maintains a robust specialized drug portfolio and generates strong free cash flow to support its operations. Johnson & Johnson...

Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?
Simply Wall St 1d
Can Johnson & Johnson Justify A Discount To Cash Flow?

has delivered a powerful run over the past few years, and with the stock now near US$269, investors are increasingly asking whether that price is fully backed b...

Can Johnson & Johnson Justify A Discount To Cash Flow?
TipRanks 3d
Michael Yee Reiterates Buy on JNJ, Maintains $320 Price Target on Caplyta’s Strong Bipolar Mania Prospects

Analyst Michael Yee from UBS maintained a Buy rating on Johnson & Johnson and keeping the price target at $320.00. Michael Yee has given his Buy rating due to...

Simply Wall St 3d
Is Johnson & Johnson Fully Priced Following Caplyta Data And Portfolio Change Talk?

Johnson & Johnson (JNJ) is back in focus after new Phase 3 data for Caplyta in bipolar I mania, with investors weighing how this potential label expansion inter...

Is Johnson & Johnson Fully Priced Following Caplyta Data And Portfolio Change Talk?

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.